Human skeletal myoblasts: who publishes what, and what they leave out

The short answer: you can buy human skeletal myoblasts today from at least six named suppliers, but almost none of them publish the specification that determines whether your muscle construct will work. Purity is stated against three different markers depending on who you ask. Passage at ship is published by exactly one supplier. Fusion index — the number that actually predicts whether myoblasts become myotubes — is published as a release criterion by nobody.

That is not a criticism of the suppliers. It is a description of the market, and it means the sourcing work here is different from buying neurons. With neurons you are normalising prices. With myoblasts you are extracting specifications that are not on the page.

Supplier table

The specification nobody publishes

Fusion index is the number that matters and it is not a release criterion anywhere.

Fusion index — the proportion of nuclei residing in multinucleated myotubes after differentiation — is the standard measure of whether a myoblast preparation will actually make muscle. It appears constantly in the literature and never on a certificate of analysis.

What suppliers publish instead is a binary: the lot was checked and it differentiates. PromoCell states that the capacity to differentiate into multinucleated syncytia is routinely checked for each lot. Cook MyoSite states that every lot must pass a differentiation test before release, with an explicit and honest carve-out for donors whose clinical condition might affect that ability. Lonza guarantees that HSMM will differentiate to form multinucleated myotubes, conditional on using their media and protocols.

Those are real assurances and they are better than nothing. They are also not a number, which means you cannot set an acceptance threshold, cannot compare two lots, and cannot write a specification that a supplier can fail. If your project depends on fusion efficiency — and any engineered muscle project does — ask for the lot’s fusion index in writing before purchase and be prepared for the answer to be that it was not measured.

Three different purity markers, three different questions

Purity in this market means at least three distinct things:

Desmin. An intermediate filament expressed in myogenic cells. Cook MyoSite specifies ≥70% desmin positive, determined by immunocytology and/or flow cytometry of desmin and myosin heavy chain. Desmin positivity says the population is myogenic. It does not say the cells are proliferation-competent satellite-derived myoblasts rather than partially differentiated cells.

Sarcomeric myosin, with negative markers. PromoCell tests each lot for sarcomeric myosin positivity and, importantly, for the absence of contaminating populations — smooth muscle α-actin negative and von Willebrand factor / Factor VIII-related antigen negative. Negative markers are underrated. Fibroblast and smooth muscle overgrowth is the classic failure mode in primary muscle culture, and a supplier that tests for what should not be there is telling you more than one that only tests for what should.

CD56 (NCAM). The surface marker used for immunomagnetic enrichment of myogenic progenitors. Cook MyoSite’s CD56-positive skMDC product is selected to >90% purity by immunomagnetic enrichment. This is the most direct measure of myogenic progenitor content in the table and the only product in this market we found that is actively selected rather than merely characterised.

A 70% desmin lot and a 90% CD56 lot are not two points on the same scale. If you are comparing suppliers on purity, first confirm you are comparing the same assay.

Passage number is published by one supplier and it matters enormously

Lonza states plainly that cryopreserved HSMM ship in second passage and proliferating HSMM ship in third passage, and that the cells are guaranteed through 10 population doublings.

That single disclosure is worth more than it appears. Primary human myoblasts lose myogenicity with passage — the population drifts toward fibroblast-like cells and fusion capacity falls. A vial at passage 2 with 10 guaranteed doublings ahead of it is a different product from a vial at passage 5, even if both say “human skeletal myoblasts” and both cost the same.

The ENCODE protocol documentation for these cells notes that primary muscle cells senesce after four to five passages, which puts the useful window in sharp relief: you are buying a finite number of doublings, and if you spend three of them expanding before you cast tissue, you have spent a third of the product.

Two operational consequences:

1. Ask for the passage number at ship from every supplier, in writing. If they will not state it, treat that as a material unknown, not a formality.
2. Count your expansion budget in doublings, not in flasks. Work backwards from the cell mass you need to cast tissue, and check it fits inside the guaranteed window.

Note also that Lonza’s performance guarantee is conditional: it holds only if their media and reagents are used exclusively and the recommended protocols are followed. That is a common structure and it is a real constraint if you have a house medium.

The primary versus iPSC-derived split

The two supply routes have completely different economics and completely different risk profiles.

Primary human myoblasts are the biologically appropriate input for most engineered muscle work. They come from a real donor with a real age, sex, BMI and, if you want it, a diagnosis. They have a finite proliferative window and they vary lot to lot, because donors vary. Pricing is either public and mid-range (PromoCell at $1,124 for >500,000 cells) or entirely quote-gated — iXCells returns no price at all for primary HSkMM, satellite cells or skeletal muscle cells, and Cook MyoSite publishes no pricing for any of its skMDC range.

iPSC-derived myocytes trade donor authenticity for consistency. bit.bio’s positioning is explicit on this point: the product exists to overcome the lot-to-lot variability and genetic drift that compromise research using primary or immortalised lines. They report contractile, striated, multinucleated myocytes by day 10 post-revival, expression of desmin, dystrophin, titin and GLUT4, spontaneous synchronised calcium waves, and contraction in response to acetylcholine. For 3D work they report muscle bundles showing twitch and tetanic forces at day 7 that strengthen over time, with pharmacological validation in both directions — inhibition with BDM, a myosin-II ATPase inhibitor, and increased contractility with caffeine.

They also sell DMD exon 44, 45, 51 and 52 deletion lines against a genetically matched wild-type control, with 3D microtissue data showing reduced contractile force and increased fatigue. If you need a dystrophy model with a real isogenic control, that pairing is difficult to assemble any other way.

The practical rule. If donor biology is the point — ageing, disease, patient-specific response — buy primary and accept the variability. If reproducibility across a screen is the point, buy iPSC-derived and accept the single genetic background. Do not buy one and hope it behaves like the other.

What the cheap option costs you

ATCC’s C2C12 mouse myoblast line is $577.00 and is the standard inexpensive substitute. It differentiates rapidly, forms contractile myotubes, and has decades of literature behind it.

It is also mouse, and immortalised. For method development, device testing, casting protocol optimisation and anything where you are validating hardware rather than biology, that is entirely appropriate and it is what most labs should use while learning to cast tissue. For anything making a claim about human muscle, it is not a substitute at any price.

iXCells also lists mouse skeletal muscle myoblasts (10MU-033) at $903.00 with dedicated growth ($338.00) and differentiation ($67.00) media, if you want primary mouse rather than an immortalised line.

Media is a large and often forgotten line item

Myoblast media is expensive relative to the cells and is frequently required to hit the datasheet performance:

• iXCells iPSC-derived myoblast expansion medium: $360.00. Differentiation medium: $149.00.
• iXCells mouse myoblast growth medium: $338.00. Differentiation medium: $67.00.
• iXCells skeletal muscle cell growth medium: $234.00.
• Lonza requires SkGM-2 BulletKit (CC-3245) for the performance guarantee to hold, plus a separate fusion medium.
• PromoCell sells a separate Skeletal Muscle Cell Differentiation Medium and offers cell KITs pairing cells with media at a discount, plus GMP-grade media on request.

Budget expansion medium and differentiation medium separately. The differentiation step also usually needs horse serum or a defined equivalent, which is a third line.

GMP and scale

None of the catalogue products above are sold as GMP material. Two routes exist if you need it:

• Cook MyoSite runs phase-appropriate GMP cell manufacturing for muscle and other adherent cells out of a 3,470 square foot ISO 7 / ISO 5 cleanroom, with cryopreservation at any scale, procurement from specific donor populations, and custom media. They have run muscle-derived cell therapy manufacturing for over two decades. Free consultation is offered. No public pricing.
• PromoCell offers GMP-grade cell culture media for skeletal muscle cells on request, and HLA-typed donors, which matters for anything heading toward a therapeutic context.

Both are quote-only and both are programmes rather than purchases.

Specification checklist

Send this and the quotes become comparable:

• Primary or iPSC-derived, and why.
• Donor age, sex, BMI and any relevant clinical history — and whether you can select the donor.
• Passage number at ship and guaranteed remaining population doublings.
• Purity specification: which marker, which assay, what threshold, and whether negative markers are tested.
• Fusion index for the specific lot, or an explicit statement that it was not measured.
• Whether every lot passes a differentiation release test.
• Cells per vial and whether the count is at freeze or viable post-thaw.
• Media required to hit the datasheet performance, and whether the performance guarantee is conditional on using it.
• Sterility, mycoplasma and viral testing panel.
• Whether an isogenic or matched control is available for a disease line.
• Total cell mass you need for the construct, worked backwards through your expansion doublings.

Where this leads

Buying the cells is the easy half. The hard half is that once you have them, no supplier will sell you a finished contractile muscle construct — they will sell you the casting device and leave the tissue to you. That gap, the real published force numbers, and who will quote a custom programme are covered in engineered skeletal muscle tissue.

If you want us to source primary myoblasts against a donor specification, or to open the quote channel on the quote-gated suppliers, send us the spec.